FDA Advisory Panel Suggests Additional Warnings for Label

About 11% of women 55 years of age and older take drugs containing bisphosphonates (including Fosamax, Aclasta, Actonel, Altevia, and Boniva) to treat and prevent osteoporosis.  This drug has been under increased scrutiny since a link was suspected between long term use and bone death (osteonecrosis) of the jaw and an increase in atypical femur [...]

September 19th, 2011|Fosamax Osteoporosis Drug|0 Comments

FDA Panel Recommends Vaginal Mesh Studies and Reclassification

On September 8, 2011, the U.S. Food and Drug Administration (“FDA”) Obstetrics and Gynecology Devices advisory panel met to discuss transvaginal mesh products which are often used to treat those with pelvic organ prolapse (POP). The panel met in response to an FDA recommendation, issued on July 12, 2011, that found "clear risks associated with [...]

September 15th, 2011|Transvaginal Mesh|0 Comments